-transparent.png){kind=logo}
Eighteen patients with advanced metastatic malignant melanoma (stage IVUICC 1987) were entered into a prospective trial with a combination of systemic fibroblast interferon-beta and recombinant interferon-gamma. Treatment was performed over a 6-week period with 3 x 5 x 10(6) U i.v. interferon-beta and 5 X 100 micrograms s.c. interferon-gamma every week. Under this therapy 16 patients showed a progressive disease, and 2 patients had a stable disease. The median time of survival was 7.5 months. Successive immunological examinations showed no significant immunomodulating effect after the 6 weeks of interferon treatment. We conclude that the combination of interferon-beta and -gamma is insufficient in the treatment of advanced metastatic malignant melanoma when administered by this dose, route and schedule.
L Kowalzick, and
U Weyer, and
P Lange, and
E W Breitbart
October 1986,
Journal of biological response modifiers,
L Kowalzick, and
U Weyer, and
P Lange, and
E W Breitbart
October 1988,
Journal of interferon research,
L Kowalzick, and
U Weyer, and
P Lange, and
E W Breitbart
December 1988,
Cancer,
L Kowalzick, and
U Weyer, and
P Lange, and
E W Breitbart
January 1996,
Cancer investigation,
L Kowalzick, and
U Weyer, and
P Lange, and
E W Breitbart
June 1989,
International journal of cancer,
L Kowalzick, and
U Weyer, and
P Lange, and
E W Breitbart
January 1996,
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy,
L Kowalzick, and
U Weyer, and
P Lange, and
E W Breitbart
September 1986,
Immunobiology,
L Kowalzick, and
U Weyer, and
P Lange, and
E W Breitbart
January 1987,
Investigational new drugs,
L Kowalzick, and
U Weyer, and
P Lange, and
E W Breitbart
July 1988,
Fortschritte der Medizin,
L Kowalzick, and
U Weyer, and
P Lange, and
E W Breitbart
April 1988,
Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis,
